Definición.
La extravasación es un proceso por el cual un líquido o droga, accidentalmente se sale fuera de su vía de administración e invade los tejidos circundantes. En los tratamientos del cáncer se refiere a infiltración inadvertida de quimioterapia en los tejidos subcutáneso o subdérmicos tras una administración intravenosa o intraarterial. (Guias ESMO 2012)
Las drogas extravasadas se clasifican en función de su daño en "vesicantes", "irritantes" y no vesicantes. Algunas drogas vesicantes también se clasificanen en las que se unen al ADN y las que no se unen al ADN. Otros autores las clasifican en vescantes, exfoliantes, irritantes, inflamatorias y neutrales.
Incidencia
Data on the incidence of either extravasation or
infiltration are scant due to the absence of a centralized register of
chemotherapy extravasation events. Incidence rates vary greatly.
Estimates between 0.01% and 7% are noted invarious publications [2–7].
Some data suggest that the incidence is decreasing probably due to
improvements in the infusion procedure, early recognition of drug
leakage and training in management techniques. A single-institution
retrospective study confirmed that the overall incidence was 10 times
less frequent in 2002 than 15 years earlier (0.01% versus 0.1%; P =
0.001) [8]. Data regarding extravasation from central venous access
devices (CVAD) are limited.
Risk factors for extravasation
Adequate identification of the
potential factors for extravasation is important to minimize the risk in
some patients. In case of an increased risk of extravasation,
preventive measures should be encouraged or in some cases,insertion of a
CVAD should be considered. These factors can be classified under
patient-associated and procedure-related risk factors [4, 7, 9].
Prevention
Most extravasations can be prevented with the
systematic implementation of careful, standardized, evidence-based
administration techniques.
In order to minimize the risk of extravasation, the staff involved in
the infusion and management of cytotoxic drugs must be trained to
implement several preventive protocols [4, 7, 9].
Should an extravasation occur, it is important to remember that the
degree of damage is dependent on the type of drug, the drug
concentration, the localization of the extravasation and the length of
time a drug develops its potential for damage.
Diagnosis
Patients must be informed to report any changes in
sensation, signs or symptoms during the i.v. administration of any
chemotherapy drug and to alert the healthcare professional to early
signs of extravasation. Particular information must be given when a
vesicant drug is administered.
Extravasation must be suspected if any of the specific signs or symptoms
are present. Initially, among the most common symptoms are feelings of
tingling, burning, discomfort/pain or swelling, and redness at the
injection site. Later symptoms may include blistering, necrosis and
ulceration.
Signs that frequently raise suspicion of an eventual extravasation are
the absence of blood return, resistance on the plunger of the syringe
during delivery of a bolus drug, or an interruption to the free flow of
an infusion.
If an extravasation is suspected, the cannula should never be removed
immediately and general and specific measures should be started.
Differential diagnosis
A differential diagnosis assessment
should be carried out if an extravasation is suspected. Some
chemotherapy drugs, even if correctly administered, can cause a local
reaction which resembles an extravasation. This should not be confused
with a true extravasation. Signs and symptoms of local nonextravasation
reactions include erythema around the cannula site and along the
accessed vein (‘flare’), urticaria and local itching. Drugs that may
cause these reactions are shown in Table 4.
Another potential differential diagnosis is chemical phlebitis. This
vein inflammation, frequently followed by a thrombosis or sclerosis of
the veins, may cause a burning sensation at the cannula site and
cramping along the vein proximal to the cannula site. This chemical
phlebitis can be caused by several drugs (see Table 4).
Management of extravasations
No randomized trials on the
treatment of extravasation have been carried out until now for ethical
reasons as well as certain difficulties in including an adequate number
of patients in such a trial. However, many extravasations may cause very
little damage if left untreated and only a comparative study with a
control group receiving the standard local care would allow clinicians
to clearly define the efficacy of an antidote.
Many of the reported management policies for extravasations are based on
non-biopsy confirmed data and in many cases, simultaneous treatment
with antibiotics was initiated. It should be also considered that many
of the recommendations date back to a drug’s original registration,
which can be several decades ago when requirements for approval were
less strict.
General measures
Regardless of the chemotherapy drug, early
initiation of treatment is considered mandatory. In this context,
patient education is crucial for a prompt identification of the
extravasation.The initiation of general unspecific measures as soon as
an extravasation is diagnosed is highly recommended[10] (See Figure 1)
[V, A]. For that purpose, it is highly recommended that every department
that administers chemotherapy has trained persons who know what to do
in case of extravasation. An extravasation kit containinginstructions,
materials and medication to handle any incidence should be always
available. An early multidisciplinary evaluation by nurses, medical
oncologists and surgeons is recommended.
Specific measures (antidotes)
Various suggestions have been
published with possible topical or injected pharmacologic methods for
certain vesicant chemotherapy drugs. One should be aware that many are
considered ineffective or further damage the extravasated area.
It should be noted that many of these substances are not available or at
best have limited access for use in many European countries [5, 7, 11].
Local injection or topical corticosteroids
A single-arm clinical
study in 53 patients with extravasations due to different drugs (21
with old lesions and 32 with recent extravasations) showed that multiple
subcutaneous injections of hydrocortisone followed with topical
betamethasone prevented tissue necrosis or sloughing necessitating
surgicaltreatment. In fact, none of the patients was submitted to
surgical debridement and all lesions were resolved. Healing time
depended on the extent of extravasation and the type of drug [12].
However, in a retrospective series of 175 cases of extravasation, up to
46% patients receiving intralesioncorticoids needed surgical debridement
versus only 13% of those without corticoids, suggesting a deleterious
effect of these agents [5, 11]. In this context, subcutaneous corticoids
are not recommended [V, C].
Sodium thiosulfate
Mechloretamine is a DNA-binding vesicant that
produces severe and prolonged skin ulceration after extravasation. In
several animal experiments, sodium thiosulfate was not able to prevent
mechloretamine skin toxicity when given i.v. immediately before or after
extravasation. However, when givenimmediately after extravasation by
intradermal injection, it had a protective effect [13]. Therefore, in
humans the recommendation in case of mechloretamine extravasation is an
immediate subcutaneous administration of 2 ml of 1/6 molar solution of
sodium thiosulfate which can be obtained bymixing 4 ml of 10% sodium
thiosulfate and 6 ml of sterile water for injection; 2 ml of the
solution is injected for each milligram of mechlorethamine suspected to
have extravasated [V, C].
DMSO
Dimethyl sulfoxide (DMSO) is a common solvent that
penetrates tissue when applied topically. This compound has free-radical
scavenging properties and has the capacity to speed up the removal of
extravasated drugs from tissues.
Despite the initial discouraging results of DMSO in animal models [14],
in the 1980s, a prospective pilot trial in 20 patients showed clinical
benefit in the management of anthracycline extravasation [15]. Topical
DMSO was appliedimmediately after extravasation covering twice the area
affected. This treatment was repeated twice daily for 14 days. No
ulceration developed and no surgical intervention was necessary.
In 1995, a series of 144 patients [3] treated with DMSO after
inadvertent extravasation secondary to several chemotherapy drugs
including doxorubicin (n = 11), epirubicin (n = 46), mytomicin (n = 5),
mitoxantrone (n = 13), cisplatin (n = 44), carboplatin (n = 6),
ifosfamide (n = 14) and fluouracil (n = 5) was reported. In these
patients, DMSO 99% was topically applied at four drops per 10 cm2 of
skin surface twice over an area that was affected and left to air dry
without dressing. The application was repeated every 8 h for 1 week.
Administration of DMSO was performed in the first 10 min after
extravasationin 84% of the patients. Only 1 patient presented ulceration
after epirubicin extravasation. Topical DMSO is a treatment option in
extravasations occurred during anthracyclines, mitomycin C or platin
salts infusion [III, B]. It should benoted that DMSO 99% can cause local
erythema which could affect the correct evaluation of the tissue
damage. Some countries have only DMSO at a concentration of 50%
available.
Dexrazoxane
Dexrazoxane has been used successfully to reduce
cardiac toxicity in patients receiving anthracycline-based chemotherapy
for cancer (predominantly women with advanced breast cancer) [16]. The
drug is thought to reduce the cardiotoxic effects of anthracyclines by
binding to free and bound iron, thereby reducing the formation of
anthracycline-iron complexes and thesubsequent generation of reactive
oxygen species which are toxic to surrounding cardiac tissue [17].
Langer et al. [18] demonstrated that systemic dexrazoxane prevented
anthracycline wound formation when administered 3 h after extravasation
in a mouse model.
One single systemic dose of dexrazoxane immediately after s.c.
administration of doxorubicin, daunorubicin, or idarubicin reduced the
tissue lesions (expressed as area under the curve of wound size times
duration) by 96%, 70%, and 87%, respectively. The protective effect of
dexrazoxane was dose-dependent and it could be administered until 3 h
later without loss of protection.
Systemic treatment with dexrazoxane recently proved to be significantly
protective in mice, against extravasation of other anthracyclines such
as amrubicin, mitoxantrone and liposomal pegylated doxorubicin [19].
Two prospective single-arm clinical trials demonstrated that i.v.
dexrazoxane prevented severe tissue damage following anthracycline
extravasation. Among the 54 patients included in the trials only one
(1.8%) finally needed surgical tissue debridement. Dexrazoxane was
administered i.v. in a 3-dayschedule (1000, 1000 and 500 mg/m2) starting
no later than 6 h after the extravasation event [20]. Dexrazoxane was
well tolerated. Hematologic toxicity, hypertransaminasemia, nausea and
local pain at the site of the dexrazoxane infusion were the most
frequent toxic effects attributed to dexrazoxane [21]. It should be
considered that in patients with creatinine clearance values <40
ml/min dexrazoxane should be reduced to 50%. DMSO should not be applied
and topical cooling (i.e. ice packs) should be removed 15 min before and
during the administration. Dexrazoxane as an i.v. administration in a
large vein in an area away from the extravasation (i.e. the opposite
arm) is recommended after anthracycline extravasation [III, B].
Hyaluronidase
Hyaluronidase is an enzyme that degradates
hyaluronic acid, improving the absorption of extravasated drugs. One
study [22] in animal models analyzed the impact on ulcer formation of
local infiltration with sodium heparine, hyaluronidase or saline.
Infiltration with hyaluronidase decreased the ulcer rateby 50–60% and
decreased ulcer size by up to 50%.
In 1994 [23], a study on seven patients with accidental vinca alkaloids
extravasation showed no skin necrosis after treatment with local
hyaluronidase. These data suggested that hyaluronidase might be
efficacious in preventing skin necrosis by extravasation due to vinca
alkaloids [V, C] (see Table 4). A dose of 1–6 ml of 150 U/ml solution is
injected through the existing i.v. line. The usual dose is 1 ml of
hyaloronidase solution for 1 ml of extravasated drug.
Surgical management of severe tissue damage
The treatment of
unresolved tissue necrosis or pain lasting more than 10 days is surgical
debridement. It is considered that only one-third of extravasations
progress to ulceration [24]. Thus, surgical procedures are relegated to
those severe extravasations or to patients in whom conservative therapy
has not been appropriately initiated. Such a procedure should consist of
wide, three-dimensional excision of all involved tissue, temporary
coverage with a biologic dressing, and simultaneous harvesting and
storage of a split-thickness skin graft. Once the wound is clean,
delayed application of the graftis performed (usually at 2–3 days) [5]
[IV, B].
Subcutaneous wash-out procedure is a surgical technique that has been
tested in 13 patients not treated with antidotes or topical treatment as
unique immediate therapy to extravasation. The mean time interval to
the subcutaneous wash-out was 345 min and none of the patients developed
atissue breakdown during a 3-month follow-up period [25]. Nevertheless,
due to scarce experience, this technique cannot be recommended as
routine management in a nonexperienced surgical unit [V, C].
Documentation
Each incident of extravasation must be correctly
documented and reported. Documentation procedure may differ between
treatment centers; however, certain items are mandatory for patient
safety and for legal purposes:(i) Patient name and number(ii) Date and
time of extravasation(iii) Name of drug extravasated as well as diluant
used (if applicable)(iv) Signs and symptoms (also reported by
patient)(v) Description of the i.v. access(vi) Extravasation area (also
the approximate amount of drug)(vii) Management steps with time and
datePhotographic documentation can be helpful for the followup
procedures and decision-making. The patient must be informed about the
scope of the problem. If a vesicant drug has extravasated, information
about the time involved in the resolution, as well as legal implications
must be addressed.
Central venous access device extravasation
Extravasation of
chemotherapy agents administered through a CVAD is a rare complication.
In a recent series of 815 patients, this complication occurred in only
0.24% [26]. In this situation, the solution may accumulate in the
mediastinum, pleura or in a subcutaneous area of the chest or neck. The
most frequent symptom of central line extravasation is acute thoracic
pain. Diagnosis must be based on clinical presentation and confirmed
with imaging techniques, usually a thoracic CT scan [V, A]. Data about
management and evolution are based on case reports. The management of
this infrequentextravasation should include stopping of the infusion and
aspiration through the central venous catheter of as much amount of the
solution as possible. If the extravasated agent is an anthracycline,
dexrazoxane might be considered as an antidote [V, C].
Although in most reported cases conservative therapy was preferred,
surgical procedures with the objective of draining the remaining
solution might be considered [V, C]. Antibiotics, i.v. corticoids,
analgesia and other treatments leading to the control of the symptoms
derived from the mediastinitis orpleuritis secondary to extravasation
can be considered [V, B] (see Figure 2).
Follow-up
Data about extravasation follow-up and management
follow-up are scarce. In order to initiate the most appropriate
follow-up, clinicians should be aware that early vesicant extravasation
signs or symptoms can be subtle and not always evident. However, in the
following days, initial inflammation increaseswith more redness, edema
and pain. Finally, depending on the vesicant drug, after several days or
weeks blisters may appear and inflammation evolve to a necrosis [27].
In this context, it is recommended that the patient should be regularly
reviewed, possibly daily or every 2 days for follow-up during the
firstweek and then weekly until complete resolution of symptoms. If
required, referral to a ( plastic) surgeon is recommendable. Patients
must be informed about the follow-up policy before leaving the treatment
area [V, B].
No hay comentarios:
Publicar un comentario